AETHLON MEDICAL INC - AEMD STOCK NEWS

Aethlon Medical (AEMD) reported financial results for the fiscal year ended March 31, 2021, highlighting a net loss of approximately $7.9 million, up from $6.4 million the previous year. Operating expenses increased to about $8.6 million, driven by higher payroll and clinical trial costs. The company raised around $17.3 million in June 2021 through various financing methods. The Aethlon Hemopurifier showed potential in treating COVID-19 patients, with successful case studies reported. As of March 31, 2021, cash reserves stood at about $9.9 million.

Aethlon Medical (AEMD) will release its financial results for Q4 fiscal year 2021 on June 24, 2021, at 4:15 p.m. ET. Management will also host a conference call at 4:30 p.m. ET the same day to discuss the results and corporate developments. The Hemopurifier, the company’s clinical-stage device, aims to treat cancer and viral infections. It holds FDA designations as a Breakthrough Device for advanced cancer and life-threatening viral infections, including COVID-19.

Aethlon Medical, Inc. (Nasdaq:AEMD) announced a registered direct offering of 1,380,555 shares at $9.00 per share, totaling approximately $12.425 million in gross proceeds. The offering is expected to close on June 14, 2021. Proceeds will be used for working capital and general corporate purposes. Additionally, Aethlon sold 626,000 shares under its At the Market Offering Agreement and will issue 1.12 million shares due to warrant exercises. The Hemopurifier, a key product, is in clinical trials for cancer treatment and COVID-19.

Aethlon Medical (Nasdaq: AEMD) announced a pre-print manuscript detailing two case studies of critically ill COVID-19 patients treated with the Hemopurifier® via Emergency Use. The first patient showed recovery signs despite previous severe viremia and achieved hospital discharge after eight treatments. The second patient demonstrated the in vivo removal of SARS-CoV-2 but unfortunately expired due to disease severity. The company is conducting an Early Feasibility Study, aiming to enroll 40 ICU COVID-19 patients. The Hemopurifier is recognized as a Breakthrough Device for both cancer and life-threatening viral infections.

Aethlon Medical, Inc. (Nasdaq: AEMD) announced its participation in two virtual conferences: the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021, and the Maxim Group and M Vest 2021 Emerging Growth Virtual Conference on March 17-18, 2021.

The company’s presentations will include details on the Aethlon Hemopurifier, a device aimed at cancer treatment and viral infections, which holds FDA Breakthrough Device designation. Webcasts will be available on demand starting March 9 at 7:00 a.m. EST.

Aethlon Medical, Inc. (AEMD) reported its financial results for the third quarter ending December 31, 2020. The company had a cash balance of $12.1 million, with government contract revenue increasing to approximately $625,000 from $413,000 year-over-year. Operating expenses surged by 137.9% to $3.07 million, largely due to payroll increases from severance costs and clinical trial expenses. Consequently, the net loss rose to about $2.44 million compared to $821,000 in the same quarter last year. Aethlon continues to develop its Hemopurifier and has initiated clinical trials for COVID-19 and cancer treatments.

Aethlon Medical, Inc. (Nasdaq: AEMD) will release its third quarter fiscal year 2021 financial results on February 10, 2021, at 4:15 p.m. EST. Management will host a conference call at 4:30 p.m. EST to review the results and discuss corporate developments. The Hemopurifier®, Aethlon's immunotherapeutic device, targets cancer and viral infections and has received FDA Breakthrough Device designations. Notably, it is currently being evaluated in a feasibility study for treating COVID-19 patients. Interested parties can register or dial in for the call.

Aethlon Medical, Inc. (Nasdaq: AEMD) announced key executive appointments on January 6, 2021, enhancing its leadership team. Guy Cipriani joins as Senior Vice President and Chief Business Officer, focusing on business development and fundraising, while Dr. Steven LaRosa becomes Chief Medical Officer, overseeing clinical operations for the Hemopurifier®. Cipriani's extensive background includes significant roles at Microbion and Cardiome Pharma, while LaRosa has clinical experience in infectious diseases. The Hemopurifier, an FDA-designated 'Breakthrough Device,' aims to address cancer and severe viral infections.

Aethlon Medical, Inc. (Nasdaq: AEMD) will present at the virtual H.C. Wainwright BioConnect 2021 Conference from Jan. 11-14, 2021. A webcast of their presentation will be available on-demand starting at 6:00 a.m. EDT on Jan. 11, accessible through their website. The company focuses on addressing unmet needs in viral diseases and cancer with its Hemopurifier device, designated as a Breakthrough Device by the FDA. It aims to combat cancer by depleting tumor-derived exosomes and has received FDA approval for an Early Feasibility Study for COVID-19 treatment.